icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
vYbX8ajhqbVmVNpy
Listen
